Harrow (HROW) Convertible Debt (2010 - 2016)

Harrow (HROW) posted quarterly Convertible Debt of $914000.0 for Q3 2016, up 20.58% quarter-over-quarter from $758000.0 in Q2 2016.

Harrow (HROW) Convertible Debt (2010 - 2016) Analysis & Trends

Harrow's Convertible Debt history runs 3 years deep, the most recent figure standing at $914000.0 for Q3 2016.

In Q3 2016, Convertible Debt changed N/A year-over-year to $914000.0; the TTM figure through Sep 2016 stood at $914000.0 (changed N/A YoY), while the FY2016 annual figure was $914000.0, changed N/A from the prior year.
Convertible Debt for Q3 2016 stood at $914000.0, up from $758000.0 in the prior quarter.
The five-year high for Convertible Debt was $914000.0 in Q3 2016, with the low at $758000.0 in Q2 2016.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	43.98 Bn	43.02 Bn	-
2	Teva Pharmaceutical Industries	43.28 Bn	39.62 Bn	2.15 Bn
3	Zoetis	31.79 Bn	30.11 Bn	1.05 Bn
4	Takeda Pharmaceutical	28.69 Bn	22.89 Bn	5.10 Bn
5	United Therapeutics	22.25 Bn	19.58 Bn	683.80 Mn
6	Viatris	18.75 Bn	17.86 Bn	1.46 Bn
7	Neurocrine Biosciences	15.58 Bn	15.19 Bn	935.80 Mn
8	Elanco Animal Health	11.87 Bn	11.34 Bn	798.00 Mn
9	Dr Reddys Laboratories	10.14 Bn	9.98 Bn	-
10	Harrow	1.58 Bn	1.49 Bn	50.36 Mn

Download Data